XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:XOMA
- CUSIP: 98419J10
- Web: www.xoma.com
Capitalization:- Market Cap: $148.69 million
- Outstanding Shares: 7,598,000
Average Prices:- 50 Day Moving Avg: $11.46
- 200 Day Moving Avg: $7.86
- 52 Week Range: $3.96 - $20.84
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.83
- P/E Growth: -0.37
Sales & Book Value:- Annual Revenue: $12.31 million
- Price / Sales: 12.08
- Book Value: ($3.83) per share
- Price / Book: -5.11
Profitability:- EBIDTA: ($30,550,000.00)
- Net Margins: -329.42%
- Return on Assets: -155.46%
Debt:- Debt-to-Equity Ratio: -0.49%
- Current Ratio: 1.08%
- Quick Ratio: 1.08%
Misc:- Average Volume: 158,597 shs.
- Beta: 3.05
- Short Ratio: 17.29
Frequently Asked Questions for XOMA Corporation (NASDAQ:XOMA)
What is XOMA Corporation's stock symbol?
XOMA Corporation trades on the NASDAQ under the ticker symbol "XOMA."
How were XOMA Corporation's earnings last quarter?
XOMA Corporation (NASDAQ:XOMA) announced its quarterly earnings data on Wednesday, November, 9th. The company reported ($2.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.40) by $0.32. The firm earned $0.64 million during the quarter, compared to the consensus estimate of $1.29 million. XOMA Corporation's revenue for the quarter was down 69.1% compared to the same quarter last year. View XOMA Corporation's Earnings History.
When will XOMA Corporation make its next earnings announcement?
Where is XOMA Corporation's stock going? Where will XOMA Corporation's stock price be in 2017?
4 brokerages have issued 12 month price targets for XOMA Corporation's shares. Their predictions range from $15.00 to $19.00. On average, they anticipate XOMA Corporation's share price to reach $17.00 in the next year. View Analyst Ratings for XOMA Corporation.
What are analysts saying about XOMA Corporation stock?
Here are some recent quotes from research analysts about XOMA Corporation stock:
- 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (9/19/2017)
- 2. Cowen and Company analysts commented, "XOMA released additional data from its Phase II studies of XOMA 358 in patients." (2/1/2017)
Who are some of XOMA Corporation's key competitors?
Some companies that are related to XOMA Corporation include Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), ContraFect Corporation (CFRX), Concordia International Corp (CXR), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Senesco Technologies (SVON) and Windtree Therapeutics (WINT).
Who owns XOMA Corporation stock?
XOMA Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.91%) and Macquarie Group Ltd. (0.53%). Company insiders that own XOMA Corporation stock include James R Neal, John Varian, Patrick J Md Phd Scannon and Paul D Rubin. View Institutional Ownership Trends for XOMA Corporation.
Who sold XOMA Corporation stock? Who is selling XOMA Corporation stock?
XOMA Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have sold XOMA Corporation stock in the last year include James R Neal, John Varian and Patrick J Md Phd Scannon. View Insider Buying and Selling for XOMA Corporation.
How do I buy XOMA Corporation stock?
Shares of XOMA Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XOMA Corporation's stock price today?
One share of XOMA Corporation stock can currently be purchased for approximately $19.57.
MarketBeat Community Rating for XOMA Corporation (NASDAQ XOMA)MarketBeat's community ratings are surveys of what our community members think about XOMA Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for XOMA Corporation (NASDAQ:XOMA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $17.00 (13.13% downside) |
Analysts' Ratings History for XOMA Corporation (NASDAQ:XOMA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/5/2017 | Wedbush | Upgrade | Neutral -> Outperform | $9.00 -> $19.00 | High |  |
| 8/10/2017 | HC Wainwright | Reiterated Rating | Buy | $15.00 | Medium | |
| 2/1/2017 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 11/16/2016 | Ladenburg Thalmann Financial Services | Reiterated Rating | Neutral | | N/A | |
| 8/5/2016 | Jefferies Group LLC | Reiterated Rating | Hold | | N/A | |
| 3/12/2016 | Piper Jaffray Companies | Reiterated Rating | Hold | | N/A | |
| 3/11/2016 | Royal Bank Of Canada | Reiterated Rating | Sector Perform | $2.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for XOMA Corporation (NASDAQ:XOMA)Earnings History by Quarter for XOMA Corporation (NASDAQ XOMA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | | | | | | | |
| 3/16/2017 | Q4 2016 | ($2.32) | ($2.89) | $0.50 million | $0.50 million | View | N/A | |
| 11/9/2016 | Q3 | ($2.40) | ($2.08) | $1.29 million | $0.64 million | View | N/A | |
| 8/3/2016 | | ($0.12) | ($0.13) | $0.84 million | $0.40 million | View | N/A | |
| 5/4/2016 | | ($0.12) | ($0.07) | $1.17 million | $3.96 million | View | N/A | |
| 3/9/2016 | Q415 | ($0.15) | $0.21 | $4.01 million | $48.18 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.16) | ($0.18) | $3.55 million | $2.10 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.18) | ($0.20) | $4.38 million | $2.54 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.16) | ($0.19) | $4.31 million | $2.65 million | View | Listen | |
| 3/11/2015 | Q414 | ($0.14) | ($0.12) | $10.70 million | $4.30 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.17) | ($0.17) | $7.00 million | $5.10 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.21) | ($0.17) | $5.32 million | $5.97 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.17) | ($0.23) | $7.40 million | $3.41 million | View | N/A | |
| 3/4/2014 | Q413 | ($0.19) | ($0.55) | $7.92 million | $8.45 million | View | N/A | |
| 11/7/2013 | Q313 | ($0.18) | ($0.21) | $7.87 million | $6.31 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.19) | ($0.21) | $9.30 million | $7.20 million | View | N/A | |
| 11/7/2012 | Q312 | ($0.21) | ($0.39) | $11.69 million | $7.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for XOMA Corporation (NASDAQ:XOMA)2017 EPS Consensus Estimate: ($2.50)
2018 EPS Consensus Estimate: ($1.81)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.65) | ($1.65) | ($1.65) |
| Q2 2017 | 1 | $0.38 | $0.38 | $0.38 |
| Q3 2017 | 1 | ($0.75) | ($0.75) | ($0.75) |
| Q4 2017 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q1 2018 | 1 | ($0.48) | ($0.48) | ($0.48) |
| Q2 2018 | 1 | ($0.51) | ($0.51) | ($0.51) |
| Q3 2018 | 1 | ($0.47) | ($0.47) | ($0.47) |
| Q4 2018 | 1 | ($0.35) | ($0.35) | ($0.35) |
(Data provided by Zacks Investment Research)
Dividend History for XOMA Corporation (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for XOMA Corporation (NASDAQ:XOMA)Insider Ownership Percentage: 3.02%
Institutional Ownership Percentage: 32.92%
Insider Trades by Quarter for XOMA Corporation (NASDAQ:XOMA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/16/2017 | John Varian | Director | Sell | 39,540 | $6.24 | $246,729.60 | |
| 3/21/2017 | James R. Neal | VP | Sell | 5,105 | $5.40 | $27,567.00 | |
| 2/1/2017 | James R Neal | VP | Sell | 195 | $4.52 | $881.40 | |
| 1/9/2017 | James R. Neal | VP | Sell | 125 | $5.15 | $643.75 | |
| 12/21/2016 | John Varian | Director | Sell | 13,549 | $5.75 | $77,906.75 | |
| 12/21/2016 | Patrick J Md Phd Scannon | VP | Sell | 3,230 | $5.75 | $18,572.50 | |
| 11/1/2016 | James R. Neal | VP | Sell | 150 | $5.25 | $787.50 | |
| 10/7/2016 | James R. Neal | VP | Sell | 2,500 | $0.45 | $1,125.00 | |
| 3/22/2016 | John Varian | CEO | Sell | 81,022 | $0.78 | $63,197.16 | |
| 3/22/2016 | Patrick J Md Phd Scannon | VP | Sell | 14,785 | $0.78 | $11,532.30 | |
| 3/22/2016 | Paul D Rubin | CMO | Sell | 24,194 | $0.78 | $18,871.32 | |
| 2/1/2016 | Patrick J Md Phd Scannon | VP | Sell | 8,000 | $1.01 | $8,080.00 | |
| 12/28/2015 | Patrick J Md Phd Scannon | VP | Sell | 8,000 | $1.37 | $10,960.00 | |
| 11/23/2015 | Patrick J Md Phd Scannon | VP | Sell | 8,000 | $1.35 | $10,800.00 | |
| 10/26/2015 | Patrick J Md Phd Scannon | VP | Sell | 8,000 | $1.04 | $8,320.00 | |
| 7/22/2015 | Bros. Advisors Lp Baker | Insider | Sell | 11,000,000 | $1.09 | $11,990,000.00 | |
| 7/15/2015 | John Varian | CEO | Sell | 10,000 | $4.49 | $44,900.00 | |
| 7/15/2015 | Paul D Rubin | CMO | Sell | 5,000 | $4.60 | $23,000.00 | |
| 7/10/2015 | Paul D Rubin | CMO | Sell | 33,400 | $4.55 | $151,970.00 | |
| 6/15/2015 | John Varian | CEO | Sell | 10,000 | $3.64 | $36,400.00 | |
| 4/15/2015 | John Varian | CEO | Sell | 10,000 | $3.86 | $38,600.00 | |
| 3/23/2015 | Paul D Rubin | CMO | Sell | 32,742 | $3.94 | $129,003.48 | |
| 3/16/2015 | John Varian | CEO | Sell | 10,000 | $3.72 | $37,200.00 | |
| 2/2/2015 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $3.52 | $17,600.00 | |
| 1/15/2015 | John Varian | CEO | Sell | 10,000 | $3.46 | $34,600.00 | |
| 1/6/2015 | Bros. Advisors Lp Baker | Director | Sell | 2,215,400 | $3.81 | $8,440,674.00 | |
| 1/2/2015 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $3.55 | $17,750.00 | |
| 12/30/2014 | Bros. Advisors Lp Baker | Director | Sell | 744,000 | $3.67 | $2,730,480.00 | |
| 12/19/2014 | Bros. Advisors Lp Baker | Director | Sell | 1,605,100 | $4.26 | $6,837,726.00 | |
| 12/16/2014 | Bros. Advisors Lp Baker | Director | Sell | 1,033,800 | $4.46 | $4,610,748.00 | |
| 12/15/2014 | John Varian | CEO | Sell | 10,000 | $4.49 | $44,900.00 | |
| 12/15/2014 | Paul D Rubin | CMO | Sell | 1,600 | $4.63 | $7,408.00 | |
| 12/9/2014 | Bros. Advisors Lp Baker | Director | Sell | 392,353 | $4.62 | $1,812,670.86 | |
| 12/4/2014 | Bros. Advisors Lp Baker | Director | Sell | 2,372,206 | $4.79 | $11,362,866.74 | |
| 12/1/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $5.51 | $27,550.00 | |
| 11/26/2014 | James R Neal | VP | Sell | 1,678 | $5.67 | $9,514.26 | |
| 11/24/2014 | James R Neal | VP | Sell | 1,032 | $5.03 | $5,190.96 | |
| 11/20/2014 | Paul D Rubin | CMO | Sell | 5,000 | $4.55 | $22,750.00 | |
| 11/13/2014 | Fred Kurland | CFO | Sell | 8,773 | $3.89 | $34,126.97 | |
| 11/13/2014 | James R Neal | VP | Sell | 4,387 | $3.89 | $17,065.43 | |
| 11/13/2014 | John Varian | CEO | Sell | 58,844 | $3.89 | $228,903.16 | |
| 11/3/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $4.33 | $21,650.00 | |
| 10/28/2014 | Paul D Rubin | CMO | Sell | 5,000 | $4.57 | $22,850.00 | |
| 10/15/2014 | John Varian | CEO | Sell | 10,000 | $3.87 | $38,700.00 | |
| 10/1/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $4.09 | $20,450.00 | |
| 9/15/2014 | John Varian | CEO | Sell | 10,000 | $4.56 | $45,600.00 | |
| 9/15/2014 | Paul D Rubin | CMO | Sell | 5,000 | $4.59 | $22,950.00 | |
| 9/4/2014 | Paul D Rubin | CMO | Sell | 10,000 | $4.56 | $45,600.00 | |
| 9/2/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $4.31 | $21,550.00 | |
| 8/18/2014 | Paul D Rubin | CMO | Sell | 26,748 | $4.34 | $116,086.32 | |
| 8/15/2014 | Fred Kurland | CFO | Sell | 10,401 | $4.31 | $44,828.31 | |
| 8/15/2014 | John Varian | CEO | Sell | 64,823 | $4.30 | $278,738.90 | |
| 8/15/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,871 | $4.31 | $25,304.01 | |
| 8/1/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $3.83 | $19,150.00 | |
| 7/15/2014 | John Varian | CEO | Sell | 10,000 | $4.03 | $40,300.00 | |
| 7/1/2014 | Patrick J Md Phd Scannon | VP | Sell | 5,000 | $4.68 | $23,400.00 | |
| 6/16/2014 | John Varian | CEO | Sell | 10,000 | $4.54 | $45,400.00 | |
| 6/16/2014 | Paul D Rubin | CMO | Sell | 11,580 | $4.54 | $52,573.20 | |
| 5/28/2014 | Paul D Rubin | CMO | Sell | 1,785 | $4.22 | $7,532.70 | |
| 5/15/2014 | John Varian | CEO | Sell | 10,000 | $3.55 | $35,500.00 | |
| 4/15/2014 | John Varian | CEO | Sell | 10,000 | $4.06 | $40,600.00 | |
| 3/18/2014 | Fred Kurland | CFO | Sell | 5,915 | $6.32 | $37,382.80 | |
| 3/18/2014 | John Varian | CEO | Sell | 21,329 | $6.32 | $134,799.28 | |
| 3/18/2014 | Patrick Md Phd Scannon | VP | Sell | 3,419 | $6.32 | $21,608.08 | |
| 3/18/2014 | Paul Rubin | CMO | Sell | 17,649 | $6.31 | $111,365.19 | |
| 3/18/2014 | Thomas Klein | Insider | Sell | 30,965 | $6.32 | $195,698.80 | |
| 3/17/2014 | John Varian | CEO | Sell | 10,000 | $6.03 | $60,300.00 | |
| 2/18/2014 | John Varian | CEO | Sell | 10,000 | $7.55 | $75,500.00 | |
| 2/18/2014 | Paul Rubin | CMO | Sell | 6,000 | $7.55 | $45,300.00 | |
| 1/21/2014 | Paul Rubin | CMO | Sell | 6,000 | $8.27 | $49,620.00 | |
| 1/15/2014 | John Varian | CEO | Sell | 10,000 | $8.28 | $82,800.00 | |
| 1/9/2014 | Patrick Md Phd Scannon | VP | Sell | 20,000 | $8.00 | $160,000.00 | |
| 12/18/2013 | Paul Rubin | CMO | Sell | 6,000 | $5.67 | $34,020.00 | |
| 12/16/2013 | John Varian | CEO | Sell | 10,000 | $5.44 | $54,400.00 | |
| 12/2/2013 | Patrick Md Phd Scannon | VP | Sell | 20,000 | $6.00 | $120,000.00 | |
| 11/27/2013 | Paul Rubin | CMO | Sell | 4,696 | $4.54 | $21,319.84 | |
| 11/18/2013 | Paul Rubin | CMO | Sell | 1,304 | $4.08 | $5,320.32 | |
| 11/15/2013 | John Varian | CEO | Sell | 64,932 | $3.95 | $256,481.40 | |
| 10/15/2013 | John Varian | CEO | Sell | 10,000 | $4.60 | $46,000.00 | |
| 9/18/2013 | Paul Rubin | CMO | Sell | 6,000 | $4.53 | $27,180.00 | |
| 9/16/2013 | John Varian | CEO | Sell | 10,000 | $4.59 | $45,900.00 | |
| 8/19/2013 | Bros. Advisors Lp Baker | Director | Buy | 2,757,791 | $3.62 | $9,983,203.42 | |
| 8/19/2013 | Paul Rubin | CMO | Sell | 6,000 | $3.74 | $22,440.00 | |
| 8/15/2013 | John Varian | CEO | Sell | 61,647 | $3.87 | $238,573.89 | |
| 8/14/2013 | Fred Kurland | CFO | Sell | 7,498 | $3.86 | $28,942.28 | |
| 8/14/2013 | Patrick Md Phd Scannon | VP | Sell | 6,002 | $3.86 | $23,167.72 | |
| 8/14/2013 | Paul Rubin | CMO | Sell | 10,520 | $3.86 | $40,607.20 | |
| 7/18/2013 | Paul D Rubin | CMO | Sell | 6,000 | $4.71 | $28,260.00 | |
| 7/15/2013 | John Varian | CEO | Sell | 10,000 | $4.81 | $48,100.00 | |
| 5/29/2013 | Paul D Rubin | CMO | Sell | 1,797 | $4.16 | $7,475.52 | |
| 5/20/2013 | Paul D Rubin | CMO | Sell | 6,000 | $0.54 | $3,240.00 | |
| 11/14/2012 | Fred Kurland | CFO | Sell | 9,111 | $2.56 | $23,324.16 | |
| 11/14/2012 | John Varian | CEO | Sell | 40,587 | $2.56 | $103,902.72 | |
| 11/14/2012 | Patrick J Md Phd Scannon | EVP | Sell | 8,773 | $2.56 | $22,458.88 | |
| 10/29/2012 | Julian Baker | Director | Buy | 4,722,666 | $3.00 | $14,167,998.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for XOMA Corporation (NASDAQ:XOMA)
Latest Headlines for XOMA Corporation (NASDAQ:XOMA)
| Source: |
|
XOMA Corporation (XOMA) Chart for Monday, September, 25, 2017
